The expanding role of systemic therapy in head and neck cancer

Journal of Clinical Oncology

Volumn 22, Issue 9, 2004, Pages 1743-1752

  Cohen, Ezra E W ^a   Lingen, Mark W ^a   Vokes, Everett E ^a  

^a University of Chicago   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CISPLATIN; TIRAPAZAMINE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; HEAD AND NECK CANCER; HUMAN; META ANALYSIS; METASTASIS; ORGAN PRESERVATION; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; XEROSTOMIA; CONTROLLED CLINICAL TRIAL; HEAD AND NECK TUMOR; PATHOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 2442655601     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.06.147     Document Type: Review

References (100)

1. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80:827-841, 1999
2. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002
3. Kotwall C, Sako K, Razack M, et al: Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg 154:439, 1987
4. Zbaeren P, Lehmann W: Frequency and sites of distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 113:762-764, 1987
5. Vokes E, Weichselbaum R, Lippman S, et al: Head and neck cancer. N Engl J Med 328:184-194, 1993
6. Lamont EB, Vokes EE: Chemotherapy in the management of squamous-cell carcinoma of the head and neck. Lancet Oncology 2:261-269, 2001
7. Forastiere A, Koch W, Trotti A, et al: Head and neck cancer. N Engl J Med 345:1890-1900, 2001
8. Adjuvant chemotherapy for advanced head and neck squamous carcinoma: Final report of the Head and Neck Contracts Program. Cancer 60:301-311, 1987
9. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer: The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324:1685-1690, 1991
10. El-Sayed S, Nelson N: Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: A meta-analysis of prospective and randomized trials. J Clin Oncol 14:838-847, 1996
11. Forastiere AA: Randomized trials of induction chemotherapy: A critical review. Hematol Oncol Clin North Am 5:725-736, 1991
12. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data-MACH-NC Collaborative Group: Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949-955, 2000
13. Domenge C, Hill C, Lefebvre JL, et al: Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 83:1594-1598, 2000
14. Paccagnella A, Orlando A, Marchiori C, et al: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86:265-272, 1994
15. Schuller DE, Metch B, Stein DW, et al: Preoperative chemotherapy in advanced resectable head and neck cancer: Final report of the Southwest Oncology Group. Laryngoscope 98: 1205-1211, 1988
16. Hennequin C, Favaudon V: Biological basis for chemo-radiotherapy interactions. Eur J Cancer 38:223-230, 2002
17. Adelstein DJ, Saxton JP, Lavertu P, et al: Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol 20:1405-1410, 2002
18. Machtay M, Rosenthal DI, Hershock D, et al: Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: A University of Pennsylvania Phase II Trial. J Clin Oncol 20:3964-3971, 2002
19. Vokes EE, Stenson K, Rosen FR, et al: Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: Curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 21:320-326, 2003
20. Kies MS, Haraf DJ, Rosen F, et al: Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 19:1961-1969, 2001
21. Wendt TG, Grabenbauer GG, Rodel CM, et al: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 16:1318-1324, 1998
22. Brizel DM, Dodge RK, Clough RW, et al: Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53:113-117, 1999
23. Adelstein DJ, Li Y, Adams GL, et al: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98, 2003
24. Calais G, Alfonsi M, Bardet E, et al: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91:2081-2086, 1999
25. Terrell JE, Fisher SG, Wolf GT: Long-term quality of life after treatment of laryngeal cancer: The Veterans Affairs Laryngeal Cancer Study Group. Arch Otolaryngol Head Neck Surg 124: 964-971, 1998
26. Browman GP, Cripps C, Hodson DI, et al: Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 12:2648-2653, 1994
27. Sanchiz F, Milla A, Torner J, et al: Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 19:1347-1350, 1990
28. Brizel DM, Albers ME, Fisher SR, et al: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798-1804, 1998
29. Jeremic B, Shibamoto Y, Milicic B, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 18:1458-1464, 2000
30. Fountzilas G, Ciuleanu E, Theophanopoulou M, et al: A randomized study of concomitant radiotherapy with cisplatin or carboplatin versus radiotherapy alone in patients with locally advanced nonnasopharyngeal head and neck cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase III study. Presented at Am Soc Clin Oncol 39th annual meeting, Chicago, IL, May 31-June 3, 2003
31. Haraf DJ, Rosen FR, Stenson K, et al: induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res 9:5936-5943, 2003
32. Vokes EE, Kies M, Haraf DJ, et al: Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: Impact on the natural history of the disease. J Clin Oncol 13:876-883, 1995
33. Hainsworth JD, Meluch AA, McClurkan S, et al: Induction paclitaxel, carboplatin, and infusional FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: A phase II trial of the Minnie Pearl Cancer Research Network. Cancer J 8:311-321, 2002
34. Lefebvre JL, Chevalier D, Luboinski B, et al: Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial-EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890-899, 1996
35. Richard JM, Sancho-Garnier H, Pessey JJ, et al: Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol 34:224-228, 1998
36. Forastiere A, Berkey B, Maor M, et al: Phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone: Intergroup Trial R91-11. Pro Am Soc Clin Oncol 20:2A, 2001 (abstr 4)
37. Jacobs C, Goffinet DR, Goffinet L, et al: Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer: A report from the Northern California Oncology Group. Cancer 60:1178-1183, 1987
38. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098, 2003
39. Weber RS, Berkey BA, Forastiere A, et al: Outcome of salvage total laryngectomy following organ preservation therapy: The Radiation Therapy Oncology Group trial 91-11. Arch Otolaryngol Head Neck Surg 129:44-49, 2003
40. Bachaud JM, Cohen-Jonathan E, Alzieu C, et al: Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial. Int J Radiat Oncol Biol Phys 36:999-1004, 1996
41. Bernier J, Domenge C, Eschwege F, Ozsahin M, et al: Chemo-radiotherapy, as compared to radiotherapy alone, significantly increases disease-free and overall survival in head and neck cancer patients after surgery: Results of EORTC Phase III Trial 22931. Presented at Am Soc Ther Radiat Oncol 43rd annual meeting, San Francisco, CA, November 4-8, 2001
42. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, et al: Postoperative concurrent radiochemotherapy in high-risk SCCA of the head and neck: Initial report of RTOG 9501/Intergroup phase III trial. Presented at Am Soc Clin Oncol 38th annual meeting, Orlando, FL, 2002
43. Laramore GE, Scott CB, al-Sarraf M, et al: Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys 23:705-713, 1992
44. Benasso M, Bonelli L, Numico G, et al: Treatment with cisplatin and fluorouracil alternating with radiation favourably affects prognosis of inoperable squamous cell carcinoma of the head and neck: Results of a multivariate analysis on 273 patients. Ann Oncol 8:773-779, 1997
45. Jacobs C, Lyman G, Velez-Garcia E, et al: A phase III randomized study comparing cisplatin and fluorouracil as single-agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10:257-263, 1992
46. Schrijvers D, Johnson J, Jiminez U, et al: Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer: Head and Neck Interferon Cooperative Study Group. J Clin Oncol 16:1054-1059, 1998
47. Forastiere AA, Metch B, Schuller DE, et al: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 10:1245-1251, 1992
48. A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. Br J Cancer 61:311-315, 1990
49. Clavel M, Vermorken JB, Cognetti F, et al: Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5:521-526, 1994
50. Forastiere AA, Leong T, Rowinsky E, et al: Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 19:1088-1095, 2001
51. Murphy B, Li Y, Cella D, et al: Phase III study comparing cisplatin (C) and 5-Fluorouracil (F) versus cisplatin & paclitaxel (T) in metastatic/recurrent head & neck cancer (MHNC). Proc Am Soc Clin Oncol 20:224a, 2001 (abstr 894)
52. De Crevoisier R, Bourhis J, Domenge C, et al: Full-dose reirradiation for unresectable head and neck carcinoma: Experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 16:3556-3562, 1998
53. Spencer SA, Harris J, Wheeler RH, et al: RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 51:1299-1304, 2001
54. Haraf DJ, Weichselbaum RR, Vokes EE: Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: A potentially curable disease. Ann Oncol 7:913-918, 1996
55. Field JK: The role of oncogenes and tumour-suppressor genes in the aetiology of oral, head and neck squamous cell carcinoma. J R Soc Med 88:35P-39P, 1995
56. Wong DT, Todd R, Tsuji T, et al: Molecular biology of human oral cancer. Crit Rev Oral Biol Med 7:319-328, 1996
57. Califano J, Westra WH, Meininger G, et al: Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res 6:347-352, 2000
58. Santini J, Formento JL, Francoual M, et al: Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13:132-139, 1991
59. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
60. Grandis JR, Tweardy DJ: TGF-alpha and EGFR in head and neck cancer. J Cell Biochem Suppl 17F:188-191, 1993
61. Grandis JR, Melhem MF, Barnes EL, et al: Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78:1284-1292, 1996
62. Grandis JR, Melhem MF, Gooding WE, et al: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832, 1998
63. Dassonville O, Formento JL, Francoual M, et al: Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11:1873-1878, 1993
64. Oc P, Modjtahedi H, Rhys-Evans P, et al: Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res 60:1121-1128, 2000
65. Oc P, Rhys-Evans P, Court WJ, et al: Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands. Clin Exp Metastasis 17:631-639, 1999
66. Barrandon Y, Green H: Cell migration is essential for sustained growth of keratinocyte colonies: The roles of transforming growth factor-alpha and epidermal growth factor. Cell 50:1131-1137, 1987
67. Chen P, Xie H, Sekar MC, et al: Epidermal growth factor receptor-mediated cell motility: Phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J Cell Biol 127:847-857, 1994
68. Veikkola T, Karkkainen M, Claesson-Welsh L, et al: Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60:203-212, 2000
69. Gille J, Swerlick RA, Caughman SW: Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. Embo J 16:750-759, 1997
70. Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350-7356, 2002
71. Magne N, Pivot X, Bensadoun RJ, et al: The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemoradiotherapy. Eur J Cancer 37:2169-2177, 2001
72. Cohen EE, Rosen F, Stadler WM, et al: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980-1987, 2003
73. Soulieres D, Senzer NN, Vokes EE, et al: Multicenter phase ii study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77-85, 2004
74. Kies M, Arquette M, Nabell L, et al: Final report of the efficacy and safety of the antiepidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 21:232A, 2002 (abstr 925)
75. Baselga J, Trigo J, Bourhis J, et al: Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc Am Soc Clin Oncol 21:226a, 2002 (abstr 900)
76. Burtness B, Li Y, Flood W, et al: Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC). Proc Am Soc Clin Oncol 21:226a, 2002 (abstr 901)
77. Clark GM, Pérez-Soler R, Siu L, et al: Rash severity is predictive of increased survival with erlotinib HCI. Proc Am Soc Clin Oncol 22:196, 2003 (abstr 786)
78. Saltz L, Kies M, Abbruzzese JL, et al: The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 22:204, 2003 (abstr 817)
79. Leonard JH, Kearsley JH, Chenevix-Trench G, et al: Analysis of gene amplification in head-and-neck squamous-cell carcinoma. Int J Cancer 48:511-515, 1991
80. Rowinsky EK, Windle JJ, Von Hoff DD: Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 17:3631-3652, 1999
81. Lobell RB, Liu D, Buser CA, et al: Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl: protein transferase and geranylgeranyl:protein transferase type-I. Mol Cancer Ther 1:747-758, 2002
82. Kelland LR, Smith V, Valenti M, et al: Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 7:3544-3550, 2001
83. Johnston SR: Farnesyl transferase inhibitors: A novel targeted therapy for cancer. Lancet Oncol 2:18-26, 2001
84. Kies M, Clayman G, El-Naggar A, et al: Induction therapy with SCH66336, a farnesyltransferase inhibitor, in squamous cell carcinoma (SCC) of the head and neck. Pro Am Soc Clin Oncol 20:225a, 2001
85. Lingen MW, Polverini PJ, Bouck NP: Retinoic acid induces cells cultured from oral squamous cell carcinomas to become antiangiogenic. Am J Pathol 149:247-258, 1996
86. Cohen RF, Contrino J, Spiro JD, et al: Interleukin-8 expression by head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 121:202-209, 1995
87. Moriyama M, Kumagai S, Kawashiri S, et al: Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol 33:369-374, 1997
88. Denhart BC, Guidi AJ, Tognazzi K, et al: Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia. Lab Invest 77:659-664, 1997
89. Inoue K, Ozeki Y, Suganuma T, et al: Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma: Association with angiogenesis and tumor progression. Cancer 79:206-213, 1997
90. Petruzzelli GJ, Benefield J, Taitz AD, et al: Heparin-binding growth factor(s) derived from head and neck squamous cell carcinomas induce endothelial cell proliferations. Head Neck 19:576-582, 1997
91. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993
92. Hori A, Sasada R, Matsutani E, et al: Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 51: 6180-6184, 1991
93. Millauer B, Shawver LK, Plate KH, et al: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579, 1994
94. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149-153, 1995
95. O'Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328, 1994
96. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997
97. Lingen MW, Polverini PJ, Bouck NP: Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Cancer Res 58:5551-5558, 1998
98. Zahalsky A, Wong RJ, Lis E, et al: Phase II trial of SU5416 in patients with advanced incurable head and neck cancer. Presented at Am Soc Clin Oncol 38th annual meeting, Orlando, FL, May 18-21, 2002
99. Winegarden J, Stenson K, Haraf D, et al: Phase I study of bevacizumab and FHX for poor prognosis head and neck cancer. Presented at Am Head Neck Soc annual meeting, 2002
100. Peters LJ: Targeting hypoxia in head and neck cancer. Acta Oncol 40:937-940, 2001